Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on June 6, 2025. The filing addresses a transition in the company's principal financial and accounting leadership effective as of the report date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
- Base Salary (New CFO): $290,000 annually.
- Target Bonus: Up to 30% of annual base salary.
- Sign-on Stipend: $25,000 one-time payment.
Material Changes
The primary material change is the departure of Robert Infarinato as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective June 6, 2025. He has been reassigned to the role of VP, Strategic Development. Concurrently, Lisa Carson, previously VP, Finance and Administration, was designated as the new PFO and PAO.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the leadership transition. Ms. Carson brings over 20 years of finance and accounting experience, including roles at Prelude Therapeutics, TELA Bio, and PhaseBio Pharmaceuticals. The filing notes that Ms. Carson is an "at-will" employee with no specified term. No specific risks, contingencies, or unusual items regarding the company's operational outlook are disclosed in this report.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for additional compensation terms or restrictive covenants.
- Confirm the effective date of the leadership transition (June 6, 2025) against internal corporate records.
- Review the press release (Exhibit 99.1) for any broader strategic context regarding the reassignment of the former CFO.
- Check subsequent filings for any impact on the company's financial reporting timeline due to the officer change.